Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
Patients with heart failure with reduced ejection fraction (HFrEF), despite optimal evidence-based treatment, have a high residual risk of adverse outcomes. The favorable results of studies on cardiovascular safety and the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patient...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-06-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3870 |
| _version_ | 1797856760045764608 |
|---|---|
| author | Zh. D. Kobalava V. V. Medovchshikov N. B. Yeshniyazov |
| author_facet | Zh. D. Kobalava V. V. Medovchshikov N. B. Yeshniyazov |
| author_sort | Zh. D. Kobalava |
| collection | DOAJ |
| description | Patients with heart failure with reduced ejection fraction (HFrEF), despite optimal evidence-based treatment, have a high residual risk of adverse outcomes. The favorable results of studies on cardiovascular safety and the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D), including outcomes associated with heart failure, were the reason for studying the effectiveness in patients with HFrEF regardless of the T2D status. For the first time in the DAPA-HF study, the SGLT2 inhibitor dapagliflozin in patients with HFrEF showed a positive effect on hard endpoints. Data of the secondary analysis confirmed the effectiveness of dapagliflozin regardless of the T2D status, therapy, age, and quality of life. The results of DAPA-HF have become a serious statement for changing the standards of the guideline-recommended therapy of HFrEF. |
| first_indexed | 2024-04-09T20:45:47Z |
| format | Article |
| id | doaj.art-8ed31595a10c4b3cbb05aafb959d9e3a |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:45:47Z |
| publishDate | 2020-06-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-8ed31595a10c4b3cbb05aafb959d9e3a2023-03-29T21:23:35Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-06-0125510.15829/1560-4071-2020-38702929Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis dataZh. D. Kobalava0V. V. Medovchshikov1N. B. Yeshniyazov2Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Patients with heart failure with reduced ejection fraction (HFrEF), despite optimal evidence-based treatment, have a high residual risk of adverse outcomes. The favorable results of studies on cardiovascular safety and the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D), including outcomes associated with heart failure, were the reason for studying the effectiveness in patients with HFrEF regardless of the T2D status. For the first time in the DAPA-HF study, the SGLT2 inhibitor dapagliflozin in patients with HFrEF showed a positive effect on hard endpoints. Data of the secondary analysis confirmed the effectiveness of dapagliflozin regardless of the T2D status, therapy, age, and quality of life. The results of DAPA-HF have become a serious statement for changing the standards of the guideline-recommended therapy of HFrEF.https://russjcardiol.elpub.ru/jour/article/view/3870heart failurereduced ejection fractiontype 2 diabetessglt2 inhibitorsdapagliflozinguideline-recommended therapydapa-hfsub-analysis |
| spellingShingle | Zh. D. Kobalava V. V. Medovchshikov N. B. Yeshniyazov Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data Российский кардиологический журнал heart failure reduced ejection fraction type 2 diabetes sglt2 inhibitors dapagliflozin guideline-recommended therapy dapa-hf sub-analysis |
| title | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data |
| title_full | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data |
| title_fullStr | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data |
| title_full_unstemmed | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data |
| title_short | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data |
| title_sort | towards quadruple therapy for heart failure with reduced ejection fraction dapa hf secondary analysis data |
| topic | heart failure reduced ejection fraction type 2 diabetes sglt2 inhibitors dapagliflozin guideline-recommended therapy dapa-hf sub-analysis |
| url | https://russjcardiol.elpub.ru/jour/article/view/3870 |
| work_keys_str_mv | AT zhdkobalava towardsquadrupletherapyforheartfailurewithreducedejectionfractiondapahfsecondaryanalysisdata AT vvmedovchshikov towardsquadrupletherapyforheartfailurewithreducedejectionfractiondapahfsecondaryanalysisdata AT nbyeshniyazov towardsquadrupletherapyforheartfailurewithreducedejectionfractiondapahfsecondaryanalysisdata |